ASCO 2017 | Pazopanib and pembrolizumab: a dangerous combination for the treatment of RCC

Simon Chowdury, MD, PhD, from the Sarah Cannon Research Institute, London, UK, discusses the KEYNOTE-018 trial, a Phase I/II study assessing the safety and efficacy of a combination of the anti-VEGF tyrosine kinase inhibitor, pazopanib, with the immune checkpoint inhibitor, pembrolizumab in treating patients with advanced renal cell carcinoma (NCT02014636). He explains that due to serious toxicity, most patients dropped out of the trial and the combination regimen was decided not to be pursued further. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.